Cost-Effectiveness of Dapagliflozin Plus Standard Treatment Compared to Standard Treatment for the Management of Heart Failure with Reduced Ejection Fraction in Colombia
Author(s)
Gil Rojas Y1, Lasalvia P2, Garcia Peña AA3
1NeuroEconomix, Bogotá, CUN, Colombia, 2NeuroEconomix, BOGOTA, CUN, Colombia, 3Hospital San Ignacio, Bogotá, Colombia
Presentation Documents
OBJECTIVES: the objective of this analysis was to evaluate the incremental cost-effectiveness of the addition of dapagliflozin to the standard treatment compared to the standard treatment in the treatment of HF with reduced ejection fraction from the perspective of the Colombian health system. METHODS: A Markov model was adapted using a hypothetical cohort of 1000 patients which was developed using information from the DAPA-HF study. Health states were the quartiles of the KCCQ-TSS, and transitory health states were included to assess the incidence of consultations and hospitalizations for heart failure. The time horizon was 5 years, and a 5% discount rate was applied, both for costs and outcomes. The information on costs and utilities was obtained from published literature. The costs were expressed in Colombian pesos as of 2020 (1 USD = $3,693.36 COP). RESULTS: In the overall analysis, the ICER of the intervention compared to the comparator was USD $5,946 per QALY gained. In the analysis by subgroups, the ICER was USD $4,881/QALY gained in those with concomitant DM2, USD $6,868 in non-diabetics, USD $6,542 in those under 65 years of age and USD $5,441 for those over 65 years of age. The calculated ICERs were below the threshold of 3 times the GDP per capita (USD $17,130) informally adopted in Colombia. CONCLUSIONS: From the perspective of the analysis, the addition of dapagliflozin to standard treatment is a cost-effective option in patients with heart failure with reduced ejection fraction in Colombia. The intervention remains a cost-effective option within the different analysis subgroups, obtaining a better cost-effectiveness ratio in patients with DM2 as comorbidity.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB161
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders, Drugs